Does Tigecycline Cause Transaminase Elevation?
Yes, transaminase elevation—specifically increases in ALT and AST—is a recognized adverse effect of tigecycline, an IV glycylcycline antibiotic used for complicated skin infections, intra-abdominal infections, and community-acquired pneumonia.[1]
How Common Is It and What Do Clinical Trials Show?
In phase 3 trials, transaminase elevations occurred in 1-15% of tigecycline patients, depending on dose and indication, compared to 0.5-10% with comparators like vancomycin or imipenem. Elevations were typically mild (up to 3x upper limit of normal) and reversible upon discontinuation. Severe cases (>10x ULN) were rare, under 1%.[1][2]
When Does It Happen and What Are Risk Factors?
Elevations often appear within the first 1-2 weeks of treatment, resolving post-therapy even if continued. Risk factors include higher doses (100 mg loading then 50 mg BID), prolonged use (>14 days), underlying liver disease, or concurrent hepatotoxins like acetaminophen. No direct causal mechanism is confirmed, but tigecycline may disrupt mitochondrial function in hepatocytes.[2][3]
What Do Prescribing Guidelines Say?
Tigecycline's US label (Tygacil) lists abnormal liver function tests, including transaminase rises, under warnings. Monitoring is advised: baseline LFTs, then weekly in hepatic impairment. Discontinue if ALT/AST exceed 5x ULN with symptoms or 10x ULN without.[1][4] EU SmPC echoes this, noting higher rates in ventilator-associated pneumonia trials.[5]
How Does It Compare to Other Antibiotics?
Tigecycline shows higher transaminase elevation rates than beta-lactams (e.g., 7% vs 4% for piperacillin-tazobactam) but similar to tetracyclines. It's less hepatotoxic than older agents like trovafloxacin, which caused fulminant hepatitis.[2][6]
Patient Concerns: Is It Dangerous?
Most cases are asymptomatic and self-limiting, with rare progression to jaundice or acute liver injury (incidence <0.5%). Post-marketing reports include drug-induced liver injury (DILI), but causality is unproven. Patients with NAFLD or alcohol use should use caution; alternatives like meropenem may be preferred.[3][7]
Sources
[1]: Tygacil US Prescribing Information (Pfizer)
[2]: Tigecycline Safety Review - Clinical Infectious Diseases (2009)
[3]: LiverTox: Tigecycline (NIH)
[4]: FDA Adverse Event Reporting System (FAERS) Data
[5]: Tygacil EU SmPC (EMA)
[6]: Antibiotic Hepatotoxicity Meta-Analysis - Hepatology (2011)
[7]: DILIN Network Case Reports on Tigecycline